Aman, J, Duijvelaar, E, Botros, L, Kianzad, A, Schippers, J, Smeele, P, Azhang, S, Bartelink, I, Bet, P, Boersma, W, Boomars, K, Bonta, P, Bos, L, Van Bragt, J, Braunstahl, G-J, Celant, L, Eger, K, Geelhoed, M, Van Glabbeek, Y, Grotjohan, H, Hagens, L, Happe, C, Heunks, L, Van Den Heuvel, M, Hoefsloot, W, Hoek, R, Hoekstra, R, Hofstee, H, Vanhove, A, Juffermans, N, Lammers, M, Kos, R, Kemper, M, Kunst, P, Van Der Lee, I, Van Der Lee, L, Mau-Asam, P, Maitland-Van Der Zee, A-H, Mieras, A, Nossent, E, Overbeek, M, Oswald, L, Paternotte, N, Pamplona, C, Pronk, N, De Raaf, M, Slob, E, Neto, A S, Schultz, M, Smit, M, Smeenk, F, Smits, J, Stalenhoef, J, Tuinman, P R, Wessels, J, Van Wezenbeek, J, Noordegraaf, A V, Handoko-De Man, F & Bogaard, H J 2021, ' Late Breaking Abstract-A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19 ', European Respiratory Journal, vol. 58 . https://doi.org/10.1183/13993003.congress-2021.OA4119 European Respiratory Journal Airway cell biology and immunopathology European Respiratory Journal, 58. European Respiratory Society
Subject
Double blind Clinical trial medicine.medical_specialty Coronavirus disease 2019 (COVID-19) business.industry Internal medicine medicine In patient Imatinib Placebo business medicine.drug